{
    "clinical_study": {
        "@rank": "65611", 
        "arm_group": [
            {
                "arm_group_label": "Fostamatinib 150 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Fostamatinib 150 milligram (mg) tablet twice daily by mouth"
            }, 
            {
                "arm_group_label": "Fostamatinib 100 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Fostamatinib 100 mg tablet twice daily by mouth"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablet twice daily by mouth"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether fostamatinib is safe and effective in the\n      treatment of IgA Nephropathy"
        }, 
        "brief_title": "Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "IGA Nephropathy", 
        "condition_browse": {
            "mesh_term": [
                "Glomerulonephritis, IGA", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Renal biopsy findings consistent with IgA nephropathy\n\n          -  Treatment with an Angiotensin Converting Enzyme inhibitor (ACEi) and/or an\n             Angiotensin II Receptor Blocker (ARB) for at least 90 days at the maximum approved\n             (or tolerated) dose\n\n          -  Proteinuria > 1 gm/day or sPCR > 100 mg/mmol at diagnosis of IgA nephropathy and\n             Proteinuria > 0.50 gm/day (sPCR > 50 mg/mmol)  at the second Screening Visit\n\n          -  Blood pressure controlled to \u2264 130/80 with angiotensin blockade with or without other\n             anti-hypertensive agents\n\n        Exclusion Criteria:\n\n          -  History of or active, clinically significant, respiratory, gastrointestinal\n             (including pancreatitis), hepatic, neurological, psychiatric, musculoskeletal,\n             genitourinary, dermatological, or other disorder\n\n          -  Have had any major cardiovascular event within the 180 days prior to randomisation,\n             including but not limited to: myocardial infarction, unstable angina, cerebrovascular\n             accident, pulmonary embolism, or New York Heart Association Class III or IV heart\n             failure.\n\n          -  Diagnosis or history suggestive of Henoch-Schonlein purpura\n\n          -  Active bacterial or parasitic infections, including tuberculosis\n\n          -  Positive serologic test for hepatitis B or hepatitis C, or subjects with suspected\n             human immunodeficiency virus (HIV)\n\n          -  Prior or current use of corticosteroids (unless for non-renal indications)\n\n          -  Prior or current use of immunosuppressive agents including cyclosporine,\n             cyclophosphamide, azathioprine, mycophenolate mofetil, Rituximab (or other anti-B\n             cell therapies)\n\n          -  Have a significant infection, an acute infection such as influenza, or who are known\n             to have an active inflammatory process at the time of Screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112838", 
            "org_study_id": "C-935788-050", 
            "secondary_id": "2014-000331-16"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fostamatinib 150 mg", 
                "description": "Fostamatinib 150 milligram (mg) tablet twice daily by mouth", 
                "intervention_name": "Fostamatinib 150 mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "R935788", 
                    "R788"
                ]
            }, 
            {
                "arm_group_label": "Fostamatinib 100 mg", 
                "description": "Fostamatinib 100 mg tablet twice daily by mouth", 
                "intervention_name": "Fostamatinib 100 mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "R935788", 
                    "R788"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo tablet twice daily by mouth", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 10, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy", 
        "overall_contact": {
            "last_name": "Daniel Magilavy, MD", 
            "phone": "650-624-1372"
        }, 
        "overall_official": {
            "affiliation": "Imperial College Renal and Transplant Centre", 
            "last_name": "(Frederick) Wai Keung Tam, MB BChir PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Agency for Health and Food Safety", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hong Kong: Department of Health", 
                "Singapore: Health Sciences Authority", 
                "Switzerland: Swissmedic", 
                "Taiwan : Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean change of proteinuria as measured by spot urine protein/creatinine ratio (sPCR)", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112838"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Rigel Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rigel Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}